| INTRODUCTION
Functional dyspepsia (FD) is defined in the ROME III criteria 1 and the updated ROME IV criteria 2 as the presence of one or more bothersome symptoms (postprandial fullness [PPF] , early satiation [ES] , epigastric pain, epigastric burning) that are unexplained after a routine clinical evaluation. The global prevalence rate of FD is reported to range between 5% and 11% when using the ROME III criteria. 3 FD encompasses two subgroups in both ROME III and ROME IV criteria, namely the Postprandial distress syndrome (PDS), which is characterized by meal-induced dyspeptic symptoms, and epigastric pain syndrome (EPS), which refers to epigastric pain or epigastric burning that does not occur exclusively postprandially. The overlap of PDS and EPS is also recognized.
The quality of life (QoL) in FD patients is known to be impaired due to symptoms causing emotional distress, problems with food and drink, and impaired vitality. 4 Furthermore, FD produces a considerable economic impact on both direct and indirect cost. In a retrospective study conducted in USA, the adjusted mean annual cost for employees with FD was more than US$5000 higher than those without FD. 5 More recent studies that directly obtained information from patients showed an estimated US$80 000 per 1000 population in USA, 6 and nearly US$60 000 per 1000 population in urban Malaysia. 7 Using the Work Productivity and Activity Impairment scale, which has also been utilized in this study, an economic loss of 99 600 Japanese Yen per patient per month has been reported in a Japanese ROME III FD patient population. 8 Acotiamide is a novel compound with fundus-relaxing and gastroprokinetic properties based on antagonism of the inhibitory muscarinic type 1 and type 2 autoreceptors on cholinergic nerve endings and acetylcholinesterase inhibition. 9 Results from clinical trials conducted in Japan have been summarized in previous review articles. 10, 11 In the pivotal Japanese phase III trial, acotiamide has shown significant improvement of overall efficacy, meal-related symptoms and QoL, with a good safety profile in patients with FD-PDS. 12 This has led to the marketing approval of acotiamide in Japan, and the inclusion of acotiamide as a treatment option in ROME IV. 13 Notably, the same trend for improvement of meal-related symptoms has been shown from the European phase IIb trial post-hoc analysis. 14 As there has been no trial conducted in the western population that assesses the long-term safety of acotiamide, the primary objective of this trial was set to evaluate the safety of acotiamide for 1 year, and secondary objectives set to explore the effect of 1 year acotiamide treatment on FD symptoms, QoL and work productivity. 
| MATERIALS AND METHODS

| Trial design
| Trial population
Key criteria for being eligible to enter the run-in period were: Adult patients aged 18 years or over; diagnosed as FD (PDS) following the ROME III criteria; most bothersome symptom being postprandial fullness (PPF) or early satiation (ES); having a normal endoscopy result; able to discontinue drugs affecting gut motility, sensitivity and/or acid secretion; without predominant symptoms of irritable bowel syndrome, gastroesophageal reflux disease or chronic idiopathic nausea.
Female patients of childbearing potential were required to agree to use acceptable contraceptive methods during the trial.
During the run-in period, patients recorded their symptoms of FD using the electronic version of the Leuven Postprandial Distress Scale (LPDS) on a daily basis. To be eligible for treatment, patients were required to fulfil the following criteria during the run-in period: at least moderate symptoms of PPF or ES for at least 2 days; without any severe/very severe heartburn; mild/moderate heartburn for less than or equal to 1 day; severe/very severe nausea for less than or equal to 2 days; weekly average of less than or equal to mild for epigastric pain and epigastric burning.
| Outcome measures
| Demographic outcomes
Information on patient demographics, medical/surgical history, prior/ concomitant medication, body weight/height, and pregnancy was
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| Safety outcomes
The primary objective of this trial was to confirm the long-term safety of 100 mg acotiamide three times daily. By this means, adverse events, ECGs, laboratory variables, vital signs, and physical examination results were recorded throughout the trial.
| Efficacy outcomes
The secondary objective of this trial was to explore the efficacy of acotiamide on FD symptoms, QoL and work productivity, by a range of validated patient reported outcome measures.
The LPDS is a validated 8-item symptom severity scale (early satiation, PPF, upper abdominal bloating, epigastric pain, epigastric burning, nausea, excessive belching, heartburn) that is recorded on a daily basis, with a grading of 0 to 4 on a 5-point Likert scale for each individual symptom, with higher scores indicating greater severity. 15 The weekly score of each symptom was calculated by taking the average of each 7-day period. The weekly change in each individual symptom score was summarized.
A patient's overall assessment of treatment efficacy was evaluated by the Overall Treatment Evaluation scale, a 7-point Likert scale ranging from "1-severely worsened" to "7-strongly improved." Recording was conducted once per week. Improvement was defined as scoring either "6-moderately improved" or "7-strongly improved."
Both generic and disease specific QoL was measured in this trial.
Short Form-36 scale is a 36-item instrument widely used to measure generic QoL. Short Form-Nepean Dyspepsia Index is a 10-item instrument that has two questions each in five subscales, with a grading of 0 to 5 on a 6-point Likert scale, with higher scores indicating greater impairment of QoL. 16 Both scales were recorded on baseline, week 12, 26, 38, and 52.
Impact of FD on work and daily activities were assessed by the Work Productivity and Activity Impairment scale, a 6-item questionnaire relating to employment status, absenteeism/presenteeism, work productivity, and activity impairment. Work productivity and activity impairment was assessed by an 11-point Likert scale, with higher scores indicating greater impediment. 17 This scale was recorded on baseline, week 12, 26, 38, and 52.
| Statistical analyses
The sample size has been set based on the ICH E1 guideline 18 rather than from statistical justifications. The guideline states that 100 patients exposed for a minimum of 1 year is considered to be acceptable to include as part of the safety data base.
Two analysis sets were defined in this trial: a safety analysis set and a full analysis set (FAS). The safety analysis set included all enrolled patients who received at least one dose of treatment and the FAS included all patients in the safety analysis set who had at least one post-baseline efficacy assessment.
| RESULTS
| Demographics
Between March 2014 and September 2015, 354 patients were screened, 297 patients proceeded to the run-in period, and 207 patients were enrolled ( Figure 2 
| Safety
The majority of patients (81.6%) maintained exposure to acotiamide for >50 weeks with a period of 320.3 ± 111.7 days (mean ± SD). The compliance to acotiamide was very high, with 91.3% of the patients having a compliance of between 80 and 120%.
The incidence of treatment-emergent adverse events (TEAEs) was 44.4%. Severity was classified as mild or moderate in 98.2% of them.
TEAEs reported in ≥4% of the total population were influenza (7.2%), headache (6.8%), and nasopharyngitis (5.8%). No chronological trend of AE occurrence was observed.
A total of 18 (8.7%) patients reported at least one treatmentrelated TEAE, and events that were reported in ≥1% of the total population were nausea (1.4%), abdominal distension (1.0%), and constipation (1.0%).
Four patients experienced severe TEAEs (feces discolored, ileus, lumbar vertebral fracture, ovarian cancer), and six patients experienced serious TEAEs (ileus, lumbar vertebral fracture and rib fracture, ovarian cancer, ligament rupture, uterine hemorrhage, prostate cancer); however, none of these were considered related to the trial drug.
There were no deaths during the trial.
Regarding adverse events that led to discontinuation of the study drug, 7 (3.4%) patients experienced a total of 11 TEAEs. This included three cases of nausea, two cases of dyspepsia, and one case each of constipation, eructation, gastrointestinal sounds abnormal, reflux gastritis, decreased appetite, and dysgeusia. One patient discontinued treatment with study drug due to pregnancy.
There has been no country specific difference regarding treatmentrelated TEAEs, and the total number of serious TEAEs, severe TEAEs or adverse events that led to discontinuation of the study drug was too small to conclude any country specific differences.
No clinically significant laboratory values or notable trends in vital signs and ECG were seen during the trial.
| Efficacy
| PDS symptom scores
At baseline, the LPDS weekly mean severity scores of PDS symptoms were 1.77 for early satiation, 2.13 for PPF, and 1.27 for upper abdominal bloating. Scores of all other symptoms were less than 0.5. During the validation of the LPDS, the minimum clinically important difference (MCID) has been determined as −0.5 on the 0-4 range. 11 Clinically important reductions from baseline in mean severity symptom score were observed from week 2 for early satiation, week 1 for PPF, and week 8 for upper abdominal bloating ( Figure 3 ).
F I G U R E 2 Patient disposition T A B L E 1 Patient demographics and disease characteristics (SAF)
Moreover, each symptom showed a continuous decrease in score throughout the 52 weeks treatment period.
| Overall treatment evaluation
The (Figure 4 ).
| Quality of life
The mean T-score and the mean change from baseline for the component summaries and each domain of SF-36 are listed in Table 2 . All domains except "Bodily pain" and "Role limitations due to emotional problems" showed an increase (improvement) over the minimally important difference 19 at Week 12 and onwards. "Bodily pain" and "Role limitations due to emotional problems" showed an increase (improvement) over the minimally important difference at Week 26 and onwards.
For the FD-specific QoL scale SF-NDI, though no statistical comparison between baseline and each timepoint has been conducted, the mean value of each domain have decreased (improvement) for all five subscale scores, with a mean change ranging between −0.8 and −1.2 at Week 12 to −0.9 and −1.5 at Week 52. The eating/drinking domain showed the largest decrease in score among the five domains ( Figure 5 ).
| Work productivity
The percentage of patients employed remained stable during the trial, within the range from 72.9% to 76.6%. Although absenteeism (work time missed) remained stable during the 52 week treatment period, presenteeism (impairment at work), work productivity and activity impairment have all shown decrease (improvement) at week 12 and onwards ( Figure 6 ).
| DISCUSSION
Following the market withdrawal of cisapride and the restriction against domperidone and metoclopramide, there is no evidence-based medication in Europe for a safe long-term usage against meal-related symptoms of FD. Multiple treatments 2, 20 and management strategy schemes 21 have been suggested, however, it is of note that treatments such as empirical use of proton-pump inhibitors are given to a large F I G U R E 3 Postprandial distress syndrome (PDS) symptom score change from baseline (Full analysis set)
number of patients and there is an unmet need for evidence-based treatment to be given. There have been multiple attempts of establishing an effective treatment for meal-related symptoms, however, many have resulted in disappointment, including the antidepressants amitriptyline and escitalopram, 22 tegaserod, 23 itopride, 24 and mosapride. 25 Moreover, when sub-grouped by FD subtypes, there were no differences in the effect of proton-pump inhibitors versus placebo, H2 receptor antagonists or prokinetics for meal-related symptoms. 26 In this article, we report the result of the first clinical trial of acotiamide that has shown the safety of acotiamide when continuously The mean change has been calculated for patients with data for both baseline and each timepoint. MID, Minimally important difference.
administered for a long-term. Such findings align with the result of past clinical trials for acotiamide. [10] [11] [12] 14, 27, 28 There has been a longterm safety trial conducted in Japan, 28 but due to the criteria for treatment cessation, only around 25% of the patients which participated in that trial had uninterrupted treatment. The current trial adds information regarding the safety of continuous acotiamide administration.
The incidence rate of overall, treatment-related, serious, or severe
TEAEs were all at a low level, comparable to that of the long-term safety trial conducted in Japan. 28 One reason for this highly safe profile would be the specificity of acotiamide to the muscarinic type 1 and 
